Literature DB >> 26626643

Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma.

Kanlayanee Sawanyawisuth1, Nattawat Tantapotinan1, Chaisiri Wongkham1, Gregory J Riggins2, Ratthaphol Kraiklang1, Sopit Wongkham1, Anucha Puapairoj1.   

Abstract

BACKGROUND AND AIM: Trophoblast cell surface antigen 2 (TROP2) or tumor-associated calcium signal transducer 2 (TACSTD2) is a 36-kDa type I transmembrane glycoprotein and exerts dual functions as an oncogene and tumor suppressor in cancer cells. In this study, we investigated the expression and functions of TROP2 in liver fluke-associated cholangiocarcinoma (CCA).
MATERIAL AND METHODS: TROP2 expression in 85 CCA tissues was detected by using immunohistochemistry. The methylation status of TROP2 promoter was studied in 15 matched pairs of normal and CCA formalin fixed paraffin embedded (FFPE) tissues using the bisulfite genomic sequencing (BGS) method. The functions of TROP2 on cancer cell behavior were investigated using siRNA in CCA cell lines. Proliferation, migration and invasion assays were performed. A PCR array was used to evaluate the impact of TROP2 knockdown on the gene expression profiles.
RESULTS: TROP2 was highly expressed in all normal bile duct epithelia, but significantly down-regulated in CCA cells. Sixty percent of CCA revealed promoter hypermethylation compared to the corresponding adjacent normal tissues. TROP2 knockdown significantly enhanced the proliferation and migration in CCA cell lines, and altered the expressions of MARCK, EMP1 and FILIP1L.
CONCLUSION: We provide new evidence that TROP2 is epigenetically down-regulated and operates as a negative regulator of cell proliferation and migration in liver fluke-associated CCA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26626643     DOI: 10.5604/16652681.1184223

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

Review 1.  Liver fluke infection and cholangiocarcinoma: a review.

Authors:  Shuohan Zheng; Yuan Zhu; Zijun Zhao; Zhongdao Wu; Kamolnetr Okanurak; Zhiyue Lv
Journal:  Parasitol Res       Date:  2016-10-08       Impact factor: 2.289

2.  Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.

Authors:  Christina Yau; Hope Rugo; Neelima Vidula
Journal:  Breast Cancer Res Treat       Date:  2022-07-04       Impact factor: 4.624

3.  The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study.

Authors:  Azza Gaber Antar Farag; Hala Said El-Rebey; Mohamed Abd El-Moneim Shoeib; Shimaa Mohammed Ahmed El-Fiky; Mustafa Elsayed Elshaib; Amal Farid Mostafa
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-06-01

4.  Silencing of the TROP2 gene suppresses proliferation and invasion of hepatocellular carcinoma HepG2 cells.

Authors:  Jian Zhang; Hai Ma; Liu Yang; Hongchun Yang; Zhenxing He
Journal:  J Int Med Res       Date:  2019-01-24       Impact factor: 1.671

Review 5.  Trop2: Jack of All Trades, Master of None.

Authors:  Sára Lenárt; Peter Lenárt; Jan Šmarda; Ján Remšík; Karel Souček; Petr Beneš
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

6.  DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.

Authors:  Olga Katzendorn; Inga Peters; Natalia Dubrowinskaja; Hossein Tezval; Pouriya Faraj Tabrizi; Christoph A von Klot; Jörg Hennenlotter; Marcel Lafos; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2021-04-21       Impact factor: 4.430

7.  Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Authors:  Peng Xu; Yang Zhao; Kang Liu; Shuai Lin; Xinghan Liu; Meng Wang; Pengtao Yang; Tian Tian; Yu-Yao Zhu; Zhijun Dai
Journal:  Cancer Manag Res       Date:  2017-12-12       Impact factor: 3.989

8.  TROP2 methylation and expression in tamoxifen-resistant breast cancer.

Authors:  Stephanie M Zimmers; Eva P Browne; Kristin E Williams; Rahul M Jawale; Christopher N Otis; Sallie S Schneider; Kathleen F Arcaro
Journal:  Cancer Cell Int       Date:  2018-07-06       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.